SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XFloki is a meme-inspired cryptocurrency project launched on the Ethereum network, themed around Elon Musk’s pet dog, who is humorously referred to as the “CEO of X.” The project aims to merge meme culture, blockchain technology, and community engagement through a decentralized platform that highlights entertainment, creativity, and innovation in Web3. XFloki distinguishes itself by combining Ethereum-based smart contracts with a strong narrative centered on Elon Musk’s symbolic leadership of X through his dog, Floki. It integrates interactive website features, governance participation, and token utility, offering the community a structured yet entertaining ecosystem rooted in transparency and decentralization.

NEW X CEO IS BACK

The community is expressing significant skepticism and frustration regarding liquidity concerns and the legitimacy of recent token listings, with many investors cautioning others about potential traps in the ecosystem.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is generating significant discussion as investors weigh the project's institutional privacy ambitions against concerns regarding its decentralized rollout and heavy Google Cloud involvement. While some in the community see the integration with traditional banking and robust ZK-proof technology as a long-term catalyst, others remain skeptical, frequently drawing comparisons to broader Cardano ecosystem volatility and past airdrop distribution challenges.

SLEEPLESS COIN

The community is debating whether this Solana-based project is a sustainable investment or another high-volatility pump-and-dump scheme amidst broader market uncertainty. Discussions center on comparing the asset to other meme coins and questioning its long-term viability despite current social media momentum.

HSBC Holdings Plc engages in the provision of banking and financial services. It operates through the following business segments: Hong Kong, the United Kingdom (UK), Corporate and Institutional Banking (CIB), International Wealth and Premier Banking (IWPB), and Corporate Centre. The Hong Kong segment consists of retail banking and wealth and commercial banking of HSBC Hong Kong and Hang Seng Bank. The UK segment covers UK personal banking and commercial banking, including HSBC Innovation Bank. The CIB segment was formed from the integration of the commercial banking business outside the UK and Hong Kong with the global banking and markets business. The IWPB segment refers to premier banking outside of Hong Kong and the UK, the Private Bank, and wealth manufacturing businesses of asset management and insurance. The Corporate Centre segment is involved in central treasury, including balance sheet management, other legacy businesses, interests in associates and joint ventures, central stewardship costs, and the UK bank levy. The company was founded on January 1, 1959 and is headquartered in London, the United Kingdom.

HSBC Holdings plc - ADR

HSBC Holdings plc

HSBC is trending following reports that it is weighing a significant, multi-year AI-driven restructuring plan that could result in the reduction of up to 10% of its global workforce. While the bank recently reported a 41% revenue surge in its latest quarterly results, investors are actively debating the long-term feasibility of using generative AI to permanently scale back middle and back-office operations without compromising service.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors monitor ongoing project development and anticipate a major tenant announcement, with sentiment heavily influenced by the firm's strategic positioning in the high-demand AI infrastructure and data center energy sector. The community is actively debating the significance of recent financing milestones, management's ability to secure large-scale contracts, and potential volatility stemming from lock-up expirations and legal headwinds.

Dogelon Mars

Dogelon Mars continues to trend on social platforms as the community maintains its strong, long-term commitment, often discussing the potential for a future breakthrough despite recent volatility. Supporters frequently compare the token's persistent branding and market cap to other major meme coins, viewing it as an overlooked project with high speculative potential.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is currently trending as investors debate the impact of upcoming smart contract integrations and the potential for tier-one exchange listings to drive future value. Community sentiment remains deeply divided, with long-term holders emphasizing the project's technical scalability and Proof-of-Work fundamentals, while critics point to stagnant price action and the lack of major exchange accessibility as primary concerns.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin continues to experience intense volatility as traders debate the long-term impact of AI-driven ad tech versus competitive threats from major industry incumbents. While bulls point to high-profile analyst upgrades and robust growth in its AXON platform as evidence of a structural moat, the stock remains a primary target for aggressive short-selling campaigns and broader market sentiment shifts.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing significant investor attention driven by anticipation of the CVS Caremark Tier 1 formulary switch and ongoing recruitment efforts to expand its sales force. The community is actively discussing the potential for a short squeeze and long-term valuation growth, while expressing optimism that the companys ophthalmic platform will demonstrate accelerating revenue momentum heading into the new year.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing extreme volatility as retail investors scramble to gain exposure to high-profile private tech companies like Anthropic and SpaceX, leading to intense debates over whether the fund's massive valuation premium is justified or an unsustainable bubble. Community sentiment is deeply polarized, with many investors holding shares for long-term venture access while others warn of a looming crash as short-sellers face significant difficulty finding borrowable shares.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Surge In Jaguar Health Stock: What's Happening Now?

Jaguar Health Inc (NASDAQ:JAGX) subsidiary, Napo Pharmaceuticals, has struck a new licensing deal with Woodward Specialty.read more...

June 26, 2025<a target="_blank" rel="noopener noreferrer nofollow" href="https://jaguarhealth.gcs-web.com/node/15251/pdf">PDF Version</a>Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of valueSAN FRANCISCO, CA / <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 26, 2025 / <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue6">Jaguar Health, Inc.</a> (<a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue7">NASDAQ:JAGX</a>) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset."Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation," said Lisa Conte, Jaguar's Founder and CEO. "Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company."Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue8">Canalevia</a>® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company.About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue9">Entheogen Therapeutics Initiative</a> (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.For more information about:Jaguar Health, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buea">https://jaguar.health</a>Napo Pharmaceuticals, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueb">www.napopharma.com</a>Napo Therapeutics, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buec">napotherapeutics.com</a>Magdalena Biosciences, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bued">magdalenabiosciences.com</a>Canalevia-CA1, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buee">canalevia.com</a>Visit the Make Cancer Less Shitty patient advocacy program on <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buef">Bluesky</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueg">X</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueh">Facebook</a> &amp; <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buei">Instagram</a>Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the Company.In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.CONTACT: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:hello@jaguar.health">hello@jaguar.health</a> Jaguar-JAGXSOURCE:&nbsp;Jaguar Health, Inc. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-board-of-directors-authorizes-company-to-include-crypto-1043232">press release</a>

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Others

Investor retail chatter spiked for Jaguar Health Inc. on Wednesday after the company revealed its plan for a $1.5 million registered direct offering priced at-the-market under Nasdaq rules.Jaguar Health shares fell 27.05% to close at $4.26 on Wednesday, before recovering 3.99% in after-hours trading to $4.43.The biopharmaceutical company finalized agreements to exchange 246,306 shares of common stock for $6.09 per share.&nbsp;Jaguar will distribute unregistered warrants in a simultaneous private placement. The exercise price is $5.84 per share, and purchasers can buy up to 492,612 shares.&nbsp;These warrants become exercisable immediately and expire after a fundamental transaction or liquidation event occurs or after 24 months, whichever condition is first met.The offering's closure is scheduled for May 22, subject to standard conditions. H.C. Wainwright &amp; Co. holds exclusive placement agency responsibilities.Jaguar plans to use net proceeds to finance general corporate purposes, such as growth capital funding, working capital maintenance, convertible note repayment, and capital expenditure needs.On Stocktwits, retail sentiment was ‘bullish’ amid a 444% surge in 24-hour message volume.Some retail traders described the offering as a “dip opportunity,” pointing to prior disclosures about share sales through the at-the-market program and suggesting the move had been anticipated since 2022.&nbsp;<stembedurl>https://stocktwits.com/jimiinfinity/message/615411703</stembedurl>Others framed the discounted pricing as a potential entry point, expressing optimism about upcoming news and the company’s trajectory.<stembedurl>https://stocktwits.com/Torobravo_1/message/615384587</stembedurl>The stock has declined 84.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’

Jaguar Health is raising $1.5 million through a registered direct offering and concurrent private warrants placement to support general corporate and growth initiatives.

Equity

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

This account has been verified as an official JAGX representative.

Verified Account

Jagaur Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar Health Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

JAGX
Jaguar Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest JAGX News

JAGXJaguar Health Inc